How Lysosomal Dysfunction Links Rare Childhood Dementia to Alzheimer’s Disease

According to a new study by researchers at UC San Diego and collaborators, published in Immunity, a single missing enzyme and a slow accumulation of cellular waste can push the brain's resident immune cells to swell and lose their way — a process that appears to drive both a devastating childhood disorder and Alzheimer's disease.

The cost of one blocked switch

Sanfilippo syndrome type A, also known as MPS IIIA, arises from a single gene variant that halts production of the enzyme sulfamidase. Normally, lysosomes — tiny organelles that break nutrients into usable energy, dismantle bacteria, and recycle worn cell parts — keep the interior of cells clean and running. Without sulfamidase, debris accumulates. Using a mouse model of MPS IIIA, the research team observed that while many cell types suffer under this load, microglia bear the worst of it. These resident immune cells expand as they clog with fats and proteins, losing their capacity to protect neighboring neurons.

A protective reflex, turned against itself

The team traced the damage to a family of proteins called MITF/TFE, which act as master genetic switches. When lysosomes inside microglia become overburdened, these switches flip from "off" to "on," reprogramming the cell's genetic activity to defend the brain. The reflex is initially protective. Over time, however, it turns maladaptive — fueling inflammation and contributing to the death of neurons the microglia were meant to safeguard.

The most striking finding came when the researchers examined microglia from people with Alzheimer's disease. The same MITF/TFE switches were activated. The convergence suggests that lysosomal failure within microglia — not only amyloid plaques acting from the outside in — can drive neurodegeneration in both the rare and the common forms of dementia.

A cleaner framework, a new lever for therapy

For first author Christopher Balak, a postdoctoral researcher in the lab of corresponding author Christopher Glass, professor of cellular and molecular medicine at UC San Diego School of Medicine, the value of MPS IIIA lies in its mechanical simplicity. "It gave us a really clear framework to study what we see in common neurodegenerative diseases and try to figure out mechanisms that are causing them," he said. Many researchers have argued that amyloid plaques, lying outside microglia, cause lysosomes to fail from the outside in. Balak's framing runs the other way: "We show in this paper that the damage can come directly from inside the cell."

By identifying MITF/TFE as the central driver of this process, the study points to a fresh target for drug development. Modulating these switches could, in principle, hold microglia in a protective state rather than letting them slip into a destructive one — a different angle from most microglia-targeted drugs, which work on receptors sitting at the cell surface.

What to watch next: replication of the MITF/TFE signal in larger Alzheimer's cohorts, and the early chemistry around compounds that can tune these switches without disturbing the rest of the cell. For now, a rare childhood disease has done something rare itself — handed researchers a clean causal foothold on a process that touches millions of aging brains.